SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Dimension Therapeutics, Inc (DMTX)

DMTX RSS Feed
Add DMTX Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 11/16/2016 7:22:37 PM - Followers: 1 - Board type: Free - Posts Today: 0
http://www.dimensiontx.com/

Portfolio of gene therapy treatment

Dimension’s programs address significant unmet medical needs for patients living with hemophilia and rare diseases associated with the liver. The Company’s lead program in hemophilia B is currently in phase I/II clinical testing. The company is also advancing programs through preclinical testing to address hemophilia A in collaboration with Bayer HealthCare and for patients living with ornithine transcarbamylase (OTC) deficiency and glycogen storage disease type Ia (GSDIa). Additional programs addressing citrullinemia type 1, phenylketonuria, and Wilson disease in candidate selection continue to broaden and expand our liver-directed rare disease platform.

Dimension’s therapies use the biology of the parvovirus (adeno-associated virus (AAV)) to carry the missing gene in the body to the target cell with the aim of correcting the defect and providing meaningful clinical benefit to the lives of patients. This platform has demonstrated early validation and compelling preclinical in vivo proof of concept across multiple disease states in leading academic research centers.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
DMTX
Current Price
Volume:
Bid Ask Day's Range
SureTrader
DMTX News: Dimension Therapeutics Announces Presentation at the 58th American Society of Hematology (ASH) Annual Meeting 08:00 AM
DMTX News: Dimension Therapeutics Receives Positive Opinion for European Orphan Drug Designation of DTX401 for the Treatment of Glycogen... 11/29/2016 08:00:00 AM
DMTX News: Notice of Effectiveness (effect) 11/23/2016 06:02:04 AM
DMTX News: Current Report Filing (8-k) 11/10/2016 08:10:49 AM
DMTX News: Securities Registration Statement (simplified Form) (s-3) 11/10/2016 08:08:31 AM
News News Alert: Dimension Therapeutics Announces Presentation at the 58th American Society of Hematology (ASH) Annual Meeting 12/05/2016 08:00:00 AM
PostSubject
#14   No worries up more than 100 % upside redsox17 11/16/16 07:22:37 PM
#13   Here’s What We Are Looking For From The trendmkr 11/15/16 02:22:38 PM
#12   Great day here redsox17 11/11/16 04:22:01 PM
#11   Jeff I am not taking profits yet. redsox17 11/11/16 12:25:19 PM
#10   Nice doji reversal pattern yesterday. Are you taking JeffAdams05 11/11/16 12:04:49 PM
#9   Hope you are enjoying this . redsox17 11/11/16 11:35:03 AM
#8   Go DMTX redsox17 11/11/16 11:22:02 AM
#7   News out redsox17 11/10/16 09:05:33 AM
#6   Great news out redsox17 11/10/16 08:52:53 AM
#5   Great news out today. redsox17 11/10/16 08:45:23 AM
#4   DIMENSION THERAPEUTICS INC. (DMTX) RECEIVES $16.33 CONSENSUS PRICE redsox17 11/07/16 04:55:58 PM
#3   there's the news... HeavyDd 10/04/16 08:08:22 AM
#2   link to FDA website... https://www.accessdata.fda.gov/scripts/opdlisting/oopd/ HeavyDd 09/30/16 07:44:16 PM
#1   DMTX drug granted orphan drug status HeavyDd 09/30/16 07:15:28 PM
PostSubject